Business Context and Reporting Period
This Form 6-K filing by Bio Blast Pharma Ltd. (referred to as Enlivex Ltd. in metadata) covers the month of March 2016, specifically reporting on a capital raise announced on March 16, 2016. The Company entered into a Co-Placement Agency Agreement with Roth Capital Partners, LLC and H.C. Wainwright & Co., LLC to facilitate a registered direct offering.
Key Financial Metrics
- Gross Proceeds: Approximately $6.7 million.
- Net Proceeds: Approximately $6.1 million (after deducting fees and expenses).
- Shares Issued: Approximately 2.16 million ordinary shares at $3.10 per share.
- Warrants Issued: Warrants to purchase up to approximately 1.08 million ordinary shares.
- Warrant Terms: Exercise price of $4.50; exercisable six months after issuance; five-and-a-half-year term.
- Placement Fees: 7% of gross proceeds plus expense reimbursement up to $35,000.
The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of new ordinary shares and warrants. The offering price of $3.10 per share represents the market valuation at the time of the transaction. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Contingencies
- Closing Date: Expected on or about March 22, 2016, subject to customary closing conditions.
- Use of Proceeds: The filing does not specify the intended use of the net proceeds.
- Risks: The closing is contingent on satisfaction of conditions; failure to meet these conditions may result in the offering not closing. Forward-looking statements regarding the closing date are not guaranteed.
- Regulatory Status: Warrants were offered in a private placement and are not registered under the Securities Act of 1933, limiting their sale in the U.S. absent registration or exemption.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected March 22, 2016) and confirm if all conditions were met.
- Confirm the final net proceeds received by the Company after all fees and expenses.
- Review the Company's subsequent filings for the specific allocation of the $6.1 million in net proceeds.
- Monitor the Company's cash position to assess runway given the lack of reported revenue in this filing.
- Check for any updates regarding the registration status of the shares underlying the warrants.